Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Debt (2016 - 2023)

Historic Non-Current Debt for Cartesian Therapeutics (RNAC) over the last 8 years, with Q2 2023 value amounting to $13.8 million.

  • Cartesian Therapeutics' Non-Current Debt fell 3908.72% to $13.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.8 million, marking a year-over-year decrease of 3908.72%. This contributed to the annual value of $17.8 million for FY2022, which is 959.18% down from last year.
  • According to the latest figures from Q2 2023, Cartesian Therapeutics' Non-Current Debt is $13.8 million, which was down 3908.72% from $16.2 million recorded in Q1 2023.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Debt ranged from a high of $25.0 million in Q1 2022 and a low of $6.4 million during Q2 2020
  • Its 4-year average for Non-Current Debt is $20.0 million, with a median of $21.3 million in 2021.
  • Per our database at Business Quant, Cartesian Therapeutics' Non-Current Debt surged by 25557.45% in 2021 and then tumbled by 3908.72% in 2023.
  • Over the past 4 years, Cartesian Therapeutics' Non-Current Debt (Quarter) stood at $24.8 million in 2020, then dropped by 20.65% to $19.7 million in 2021, then dropped by 9.59% to $17.8 million in 2022, then dropped by 22.48% to $13.8 million in 2023.
  • Its last three reported values are $13.8 million in Q2 2023, $16.2 million for Q1 2023, and $17.8 million during Q4 2022.